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ABSTRACT
The tropomyosin receptor kinase (Trk) receptor family
comprises 3 transmembrane proteins referred to as Trk
A, B and C (TrkA, TrkB and TrkC) receptors that are
encoded by the NTRK1, NTRK2 and NTRK3 genes,
respectively. These receptor tyrosine kinases are
expressed in human neuronal tissue and play an
essential role in the physiology of development and
function of the nervous system through activation by
neurotrophins. Gene fusions involving NTRK genes
lead to transcription of chimeric Trk proteins with
constitutively activated or overexpressed kinase
function conferring oncogenic potential. These genetic
abnormalities have recently emerged as targets for
cancer therapy, because novel compounds have been
developed that are selective inhibitors of the
constitutively active rearranged proteins. Developments
in this field are being aided by next generation
sequencing methods as tools for unbiased gene
fusions discovery. In this article, we review the role of
NTRK gene fusions across several tumour histologies,
and the promises and challenges of targeting such
genetic alterations for cancer therapy.
INTRODUCTION
The treatment of solid tumours is dramatic-
ally changing in recent years thanks to the
enhancement of molecular diagnostic tech-
nologies leading to identiﬁcation of an
increasing number of speciﬁc actionable
oncogenic abnormalities such as gene activat-
ing point mutations, in-frame insertions/dele-
tions and ampliﬁcation or rearrangements.
The concept of precision medicine consists in
the accomplishment of therapy individualised
to each tumour by exploiting these alterations
as predictive biomarkers as well as targets of
therapy. Neurotrophic tropomyosin receptor
kinase (NTRK) gene rearrangements have
recently emerged as targets for cancer
therapy, because novel compounds have been
developed that are selective inhibitors of the
constitutively active fusion proteins that
arise from these molecular alterations.
Developments in this ﬁeld are being aided by
next generation sequencing methods as tools
for unbiased gene fusion discovery. In this
article, we review the role of NTRK gene
fusions across several tumour histologies, and
the promises and challenges of targeting such
genetic alterations for cancer therapy.
TROPOMYOSIN RECEPTOR KINASE (TRK)
FAMILY OF RECEPTORS
The Trk receptor family comprises three
transmembrane proteins referred to as Trk A,
B and C (TrkA, TrkB and TrkC) receptors,
and are encoded by the NTRK1, NTRK2 and
NTRK3 genes, respectively. These receptor
tyrosine kinases (TK) are expressed in
human neuronal tissue, and play an essential
role in both the physiology of development
and function of the nervous system through
activation by neurotrophins (NTs).1 The
latter are speciﬁc ligands known as nerve
growth factor (NGF) for TrkA, brain-derived
growth factor (BDGF), and NT-4/5 for TrkB
and NT3 for TrkC, respectively.2 All three Trk
receptors are structured with an extracellular
domain for ligand binding, a transmembrane
region and an intracellular domain with a
kinase domain. The binding of the ligand to
the receptor triggers the oligomerisation of
the receptors and phosphorylation of speciﬁc
tyrosine residues in the intracytoplasmic
kinase domain. This event results into the
activation of signal transduction pathways
leading to proliferation, differentiation and
survival in normal and neoplastic neuronal
cells1 (ﬁgure 1). The binding of TrkA recep-
tor by NGF causes the activation of the Ras/
Mitogen activated protein kinase (MAPK)
pathway, which leads to increased prolifer-
ation and cellular growth through extracellu-
lar signal-regulated kinase (ERK) signalling.
Other pathways such as phospholipase C-γ
(PLCγ) and PI3K are also activated. TrkC
coupling with NT3 causes preferential activa-
tion of the PI3/AKT pathway preventing
apoptosis and increasing cell survival,
whereas TrkB transduces the BDNF signal via
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Ras-ERK, PI3K and PLCγ pathway, resulting in neuronal
differentiation and survival.1 The Trk receptor kinases
play a key role in central and peripheral nervous system
development as well as in cell survival. The proper regu-
lation of Trk receptor levels and their activation is critic-
ally important in cell functioning, and the upregulation
of Trk receptors has been reported in several central
nervous system-related disorders (eg, TrkB in epilepsy,
neuropathic pain, or depression).3
The NTRK1 gene is located on chromosome
1q21-q22,4 and its mutations disrupting the function of
the TrkA protein are found in patients affected by con-
genital insensitivity to pain with anhidrosis (CIPA) syn-
drome.5 In 1999 Indo et al cloned the full-length NTRK1
human gene encoding a 790-residue or 796-residue
protein (TrkA receptor) with an intracellular domain
containing a juxtamembrane region, a TK domain and a
short C terminal tail.6
The NTRK2 gene is mapped on chromosome 9q22.17
and contains 24 exons,8 coding for a protein of 822
amino acid residues (TrkB receptor). The full-length
TrkB receptor contains an N-terminal signal sequence,
followed by a cysteine-rich domain, a leucine-rich
domain, a second cysteine-rich domain, 2 immunoglobu-
lin (Ig)-like domains that make up the BDNF-binding
region, a transmembrane domain, a Src homology 2
domain containing (SHC)-binding motif, a TK domain
near the C terminus and a C-terminal PLCγ-docking site.
The NTRK3 gene is located on chromosome 15q25,9
and its transcription product known as TrkC was isolated
and characterised by Lamballe et al10 in 1991. TrkC
receptor is a glycoprotein of 145 kD preferentially
expressed in the human hippocampus, cerebral cortex
and in the granular cell layer of the cerebellum.
MOLECULAR ALTERATIONS OF NTRK GENES IN VARIOUS
MALIGNANCIES ACROSS HISTOLOGIES
Gene fusions of NTRK genes represent the main molecu-
lar alterations with known oncogenic and transforming
Figure 1 Schematic view of Trk receptors signalling, showing the three major pathways involved in cell differentiation and
survival. AKT, v-akt murine thymoma viral oncogene homologue; BDGF, brain-derived growth factor; DAG, diacyl-glycerol; ERK,
extracellular signal-regulated kinase; GAB1, GRB2-associated-binding protein 1; GRB2, growth factor receptor-bound protein 2;
IP3, inositol trisphosphate; MEK, mitogen-activated protein kinase; NGF, nerve growth factor; NTF-3, neurotrophin 3; PI3K,
phosphatidylinositol-4,5-bisphosphate 3-kinase; PIP2, phosphatidylinositol 4,5-bisphosphate; PKC, protein kinase C; PLC,
phospholipase C; RAF, rapidly accelerated fibrosarcoma kinase; RAS, rat sarcoma kinase; SHC, Src homology 2 domain
containing.
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potential.11 Less common oncogenic mechanisms that
have been described are in-frame deletion of NTRK1 in
acute myeloid leukaemia12 and a TrkA alternative spli-
cing in neuroblastoma.13 In all reported Trk oncogenic
gene fusions, the 3’ region of the NTRK gene is joined
with a 5’ sequence of a fusion partner gene by an intra-
chromosomal or interchromosomal rearrangement, and
the oncogenic chimaera is typically a constitutively acti-
vated or overexpressed kinase (ﬁgure 2). Table 1 shows
the NTRK fusions reported to date and their associated
cancer types.
Colorectal adenocarcinoma: It has been believed for more
than three decades since the seminal work of Fearon
and Vogelstein14 on molecular carcinogenesis of colorec-
tal carcinoma (CRC), that rearrangement of oncogenes
are of such low prevalence, as compared with DNA
sequencing alteration or ampliﬁcations, that their role is
almost negligible in the genesis of this tumour type. The
ﬁrst published report of a NTRK rearrangement in CRC
dates back to 1986,15 when a TPM3-NTRK1 translocation
was detected in a tumour biopsy, and thereafter very
little has been reported about these gene defects in
CRC. However, the NTRK gene fusions and their onco-
genic potential in this tumour as oncogenes may have
been underestimated, mostly because of the absence,
until recently, of targeted therapies exploiting these
gene abnormalities. These circumstances resemble what
previously occurred with ALK (Anaplastic Lymphoma
Kinase) gene fusions in non-small cell lung cancer
(NSCLC), in which despite evidence of ALK fusions
since 2007,16 the scientiﬁc interest was raised only after
synthesis of compounds with ALK-speciﬁc inhibitory
activity.17 In particular, in 2014, Ardini et al reported the
characterisation of the TPM3-NTRK1 gene rearrange-
ment as a recurring, although rare, event in CRC, and
also discovered entrectinib (NMS-P626; RXDX-101) as a
novel, highly potent and selective pan-Trk inhibitor.
Entrectinib suppressed TPM3-TRKA phosphorylation
and downstream signalling in KM12 cells and showed
remarkable antitumour activity in mice bearing KM12
tumours. Also, in 2015, Créancier et al18 reported the
0.5% prevalence of NTRK fusions in 408 CRC clinical
samples, including a TPM3-NTRK1 (TRK-T2 fusion).
Recently, in the molecular screening within the phase I
ﬁrst-in-human study of entrectinib (EudraCT number:
2012-000148-88), an abnormal expression of the TrkA
protein was identiﬁed in tumour and liver metastases of
a patient with CRC refractory to standard therapy, and
molecular characterisation unveiled a novel
LMNA-NTRK1 rearrangement within chromosome 1,
with oncogenic potential. The patient was treated with
entrectinib, achieving objective partial response with
decrease of metastatic lesions in the liver and adrenal
gland.19 Further, as a part of the molecular screening of
Figure 2 The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion
partner. Oligomerisation of the chimeric protein is the main proposed mechanisms for increased tumour cell survival and
proliferation via the known pathways of Trk receptors. (A) NTRK1 gene with 17 exon sequences and respective TrkA protein
regions.5 (B) Mechanism of entrectinib (E) action and the known mechanisms of acquired resistance (point mutation G595R
and G567C) to E.50 Cys, cysteine clusters; Ig1 and Ig2, first and second immunoglobulin-like motifs, respectively; LRM,
leucine-rich motifs; SP, signal peptide; TK, tyrosine kinase; TM, transmembrane.
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the Memorial Sloan Kettering IMPACT (MSK-IMPACT)
programme,20 Braghiroli et al21 reported a 4% (2 of the
49 cases) of incidence of NTRK unidentiﬁed fusions in
appendiceal adenocarcinoma.
Lung adenocarcinoma: Gene rearrangements have
already emerged as therapeutic targets in NSCLC,22
since Food and Drug Administration (FDA) and
European Medicines Evaluation Agency (EMEA)
Table 1 Reported gene fusions involving NTRK genes along with the corresponding tumour
Gene fusion Cancer type Authors (year)
NTRK1
LMNA-NTRK1 Colorectal Sartore-Bianchi et al (2016)
Soft tissue sarcoma Doebele et al (2015)
Spitzoid melanomas Wiesner et al (2014)
AYA sarcoma Morosini et al (2015)
Congenital infantile fibrosarcoma Wong et al (2015)
TPM3-NTRK1 Colorectal Lee et al (2015), Créancier et al (2015), Ardini et al (2014)
Papillary thyroid carcinomas Bongarzone et al (1989), Butti et al (1995)
Glioblastoma Wu et al (2014)
SQSTM1-NTRK1 NSCLC Farago et al (2015)
NTRK1-SQSTM1 NSCLC Siena et al (2015)
NFASC-NTRK1 Glioblastoma multiforme Frattini et al (2013), Kim et al (2014)
BCAN-NTRK1 Glioblastoma multiforme Kim et al (2014), Frattini et al (2013)
PPL-NTRK1 Thyroid carcinoma Farago et al (2015)
RFWD2-NTRK1 Large cell neuroendocrine tumour
(lung)
Fernandez-Cuesta et al (2014)
CD74-NTRK1 Lung adenocarcinomas Vaishnavi et al (2013)
MPRIP-NTRK1 Lung adenocarcinomas Vaishnavi et al (2013)
RABGAP1L-NTRK1 ICC Ross et al (2014)
TFG-NTRK1 Thyroid carcinomas Greco et al (1995)
TP53-NTRK1 Spitzoid melanomas Wiesner et al (2014)
NTRK2
Unknown-NTRK1 Appendiceal adenocarcinoma Braghiroli et al (2016)
AFAP1-NTRK2 Low-grade glioma Stransky et al (2014)
AGBL4-NTRK2 Glioblastoma Wu et al (2014)
NACC2-NTRK2 Pilocytic astrocytomas Jones et al (2013)
PAN3-NTRK2 Head and neck squamous cell
carcinoma
Wu et al (2014)
QKI-NTRK2 Pilocytic astrocytomas Jones et al (2013)
TRIM24-NTRK2 Lung adenocarcinoma Wu et al (2014)
VCL-NTRK2 Glioblastoma Wu et al (2014)
NTRK3
ETV6-NTRK3 Glioblastoma Zhang et al (2013)
Glioblastoma Wu et al (2014)
MASC Tognon et al (2002), Ito et al (2015), Del Castillo et al (2015)
Ductal carcinoma Makretsov et al (2004), Arce et al (2005), Lagree et al (2011),
Pinto et al (2014)
Fibrosarcoma Morerio et al (2004), Punnett et al (2000)
Congenital mesoblastic nephroma Watanabe et al (2002)
Radiation-associated thyroid cancer Leeman-Neill et al (2014)
AML Kralik et al (2011), Eguchi et al (1999), Knezevich et al (1998)
GIST Brenca et al (2015)
MASC of salivary gland Urano et al (2015), Skàlovà et al (2015)
Papillary thyroid cancer Leeman-Neill et al (2014), Seungbok Lee et al (2014)
Colorectal Hechtman et al (2015)
BTBD1-NTRK3 Glioblastoma Wu et al (2014)
AFAP1, actin filament-associated protein 1; AGBL4, ATP/GTP-binding protein-like 4; AML, acute myeloid leukaemia; AYA, adolescents and
young adults; BCAN, brevican; BTBD1, BTB (POZ) domain containing 1; CD74, CD74 molecule; ETV6, ets variant 6; GIST, gastrointestinal
stromal tumor; ICC, intrahepatic cholangiocarcinoma; LMNA, lamin A/C; MASC, mammary secretory breast carcinoma; MPRIP, myosin
phosphatase Rho interacting protein; NACC2, NACC family member 2, BEN and BTB (POZ) domain containing; NFASC, neurofascin;
NSCLC, non-small cell lung cancer; PAN3, PAN3 poly(A) specific ribonuclease subunit; PPL, periplakin; QKI, KH domain containing RNA
binding; RABGAP1L, RAB GTPase activating protein 1-like; RFWD2, ring finger and WD repeat domain 2, E3 ubiquitin protein ligase;
SQSTM1, sequestosome 1; TFG, TRK-fused gene; TP53, tumour protein p53; TPM3, tropomyosin 3; TRIM24, tripartite motif containing 24;
VCL, vinculin.
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approval of crizotinib for patients with NSCLC harbour-
ing EML4-ALK translocations. In 2013, Vaishnavi et al23
described two different gene fusions involving the
NTRK1 gene that lead to constitutive TrkA TK domain
activation. The ﬁrst was characterised by a rearrange-
ment of the 5’ portion of the myosin phosphatase
Rho-interacting protein (MPRIP) gene fused to the 3’
portion of NTRK1; the resultant protein (RIP-TrkA)
encoded by this fusion showed in cultured cells autopho-
sphorylation of the fusion protein at critical tyrosine resi-
dues in cultured cells, implying its constitutive
activation. The second gene fusion was characterised by
a rearrangement between the CD74 and NTRK1 gene.
In the same study, the authors also reported a
TPM53-NTRK1 fusion (similar to that already described
in CRC). A total of 3.3% patients in this study (3/91)
harboured NTRK rearrangements potentially susceptible
to TrkA inhibitors. In 2014, Stransky et al24 identiﬁed a
novel TRIM24-NTRK2 gene fusion in lung adenocarcin-
oma through an unbiased computational pipeline
designed for the identiﬁcation of gene fusions in the
data set from The Cancer Genome Atlas (TCGA).
Papillary thyroid carcinoma (PTC): A few years after the
ﬁrst published paper of a NTRK rearrangement in colo-
rectal cancer, Bongarzone et al25 in 1989 described an
oncogenic version of NTRK1 in PTC. Further works
showed that oncogenic NTRK1 rearrangements in PTC
are the consequence of the fusion of the TK domain of
NTRK1 oncogene with 5-terminal sequences of at least
three different genes. TRK-T1 and TRK-T2 are two dif-
ferent hybrid forms derived from chromosome inversion
and different portions of TPR (Translocated Promoter
Region) gene on chromosome 1q25 activate them.
Another NTRK1 oncogene obtained by fusion with the
TFG gene (TRK fused gene) on chromosome 3 is TRK–
T3. All these oncogenic forms of NTRK1 gene encode
cytoplasmic hybrid proteins that are constitutively phos-
phorylated at tyrosine residues.26 Somatic rearrange-
ments of the NTRK1 gene in PTC usually do not exceed
12%, but range quite widely across different populations
(from 15% to 50% in the Italian population27 to <10%
in French,28 Japanese29 and Chinese30). A rare chromo-
somal rearrangement in sporadic thyroid cancer, but
more frequent in radiation-related tumours, is
ETV6-NTRK3, which results from an interchromosomal
translocation t(12;15)(p13;q25) that juxtaposes exons
1–4 of ETV6 to exons 12–18 of NTRK3. The breakpoint
differs from those reported in congenital ﬁbrosarcomas
and secretory breast cancers.31 Recently, via unbiased
genomic approaches, novel gene rearrangements have
been described in PTC, such as the PPL-NTRK1 (from
periplakin, PPL)32 and the RBPMS-NTRK3 (from the
RNA-binding protein with multiple splicing, RBPMS)
gene fusion.24
Human secretory breast carcinoma: This is a rare but dis-
tinct subtype of inﬁltrating ductal carcinoma that was
originally described in children and adolescents, but is
now known to occur with equal incidence in adults. In
2002, Tognon et al33 reported the ETV6-NTRK3 gene
fusion t(12;15)(p12;q26.1) as a pathognomonic genetic
feature of this rare carcinoma.
Glioblastoma: Gene fusions occur in approximately 30–
50% of patient with glioblastoma (GBM) samples and
the Trk family could play a very important role. In 2013,
Frattini et al34 analysed 185 GBM samples and found two
in-frame fusions involving NTRK1 (BCAN-NTRK1 and
NFASC-NTRK1). In the same year, Shah et al35 conﬁrmed
such genomic events as recurrent in a cohort of 24 GBM
samples. In their work based on wide genomic screening
of formalin-ﬁxed parafﬁn-embedded (FFPE) specimens,
Zheng et al32 reported one in-frame fusion involving
exon 21 of ARHGEF2 (encoding Rho/Rac guanine
nucleotide exchange factor 2) and exon 10 of NTRK1,
and two in-frame fusions involving exon 5 of CHTOP
(encoding the chromatin target of PRMT1) and exon
10 of NTRK1, of the 115 brain tumour FFPE analyses. In
2014, Wu et al36 applied a whole genome, whole exome
and/or transcriptome sequencing to 127 samples of
paediatric high-grade glioma (HGG), identifying recur-
rent fusions involving the neurotrophin receptor genes
NTRK1, 2, or 3 in 40% of non-brainstem HGG.
Miscellaneous tumours: The recent efforts for identifying
targetable genomic alterations through the use of next
generation sequencing (NGS) are leading to the identi-
ﬁcation of novel and recurrent gene fusions in other
various types of cancer. Ross et al37 reported a NGS
screening of 28 FFPE samples of intrahepatic cholangio-
carcinoma, in which a novel gene fusion
RABGAP1L-NTRK1 was identiﬁed from a liver biopsy of
a 62-year-old woman. Further, a recurrent gene fusion
involving the ETV6 and the NTRK3 gene
(ETV6-NTRK3) has been described in congenital
ﬁbrosarcoma.38
TRK INHIBITORS
The growing number of identiﬁed gene fusions involv-
ing the NTRK gene enhanced the interest of the scien-
tiﬁc community in the development of drugs with
inhibitory capacity for the TK domain of Trk. Bertrand
et al39 published the high-resolution crystal structures of
TrkA and TrkB in their apo-forms, as well as in complex
with three nanomolar inhibitors. At least 40 residues of
the kinase domain in its Asp-Phe-Gly (DFG)-in conform-
ation, which potentially interact with a ligand in the
ATP-binding site, are highly conserved between Trk pro-
teins. Only 2 of the 40 residues are different between
TrkA and TrkB, whereas the TrkB and TrkC ATP-binding
sites are identical,39 suggesting an easier design of pan-,
rather than selective, inhibitors of the three distinct iso-
forms of Trk receptors. Even though this may be an
issue in developing selective Trk agonists for the treat-
ment of neurological diseases,3 40 it may be indeed
advantageous for cancer treatment where inhibition of
all three Trk members’ gene fusions translates into
wider antitumour activity.41
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There is a limited number of reported Trk receptor
tyrosine-kinase inhibitors in the literature and only a few
of these have been tested in clinical trials (table 1).
Entrectinib, formerly RXDX-101 and NMS-E628, is an
orally bioavailable inhibitor of the TK TrkA, TrkB and
TrkC, as well as of C-ros oncogene 1 (ROS1) and
Table 2 Ongoing phase I/II trials involving drugs with known inhibitory activity of NTRK-related kinases
NCT/EudraCT
number Title Drug Targets Phases Patients Start date
NCT02219711 Phase 1/1b study of MGCD516 in
patients with advanced cancer
MGCD516 MET, AXL,
c-kit, MER,
DDR2,
VEGFR,
PDGFR, RET,
Trk, Eph
1 120 August 2014
NCT02568267 Basket study of entrectinib
(RXDX-101) for the treatment of
patients with solid tumors harboring
NTRK1/2/3, ROS1, or ALK gene
rearrangements (fusions)
Entrectinib
(RXDX-101)
TrkA, TrkB,
TrkC,
ROS1, ALK
2 300 October
2015
NCT02097810 Study of oral RXDX-101 in adult
patients with locally advanced or
metastatic cancer targeting NTRK1,
NTRK2, NTRK3, ROS1, or ALK
molecular alterations
1/2 175 June 2014
NCT02650401 Study of RXDX-101 in children with
recurrent or refractory solid tumors and
primary CNS tumors
1 80 December
2015
NCT02048488/
2013–000686–
37
A phase I/IIa open-label, dose
escalation and cohort expansion trial
of oral TSR-011 in patients with
advanced solid tumors and
lymphomas
TSR-011 TrkA, ALK 1/2 150 October
2012
NCT02637687 Oral TRK inhibitor LOXO-101 for
treatment of advanced pediatric solid
or primary central nervous system
tumors
LOXO-101 TrkA, TrkB,
TrkC
1 36 December
2015
NCT02122913 Oral TRK inhibitor LOXO-101 for
treatment of advanced adult solid
tumors
1 108 April 2014
NCT02576431 Study of LOXO-101 in subjects with
NTRK fusion positive solid tumors
2 151 October
2015
NCT01639508 Cabozantinib in patients with RET
fusion-positive advanced non-small
cell lung cancer and those with other
genotypes: ROS1 or NTRK fusions or
increased MET or AXL activity
Cabozantinib
(XL184)
TrkA, RET,
ROS1, MET,
AXL
2 68 July 2012
NCT01804530 Phase 1 study of PLX7486 as single
agent and with gemcitabine plus
nab-paclitaxel in patients with
advanced solid tumors
PLX7486 TrkA, TrkB,
TrkC, FMS
1 160 August 2013
NCT02279433 A first-in-human study to evaluate the
safety, tolerability and
pharmacokinetics of DS-6051b
DS-6051b TrkA,TrkB,
TrkC, ROS1
1 70 September
2014
2013–003009–
24
Phase I-II study of F17752 in patients
with advanced solid tumours
F17752 ALK, ROS1,
Trk
1/2 112 September
2015
NCT02228811 A study of DCC-2701 in participants
with advanced solid tumors
Altiratinib
(DCC-2701)
TrkA, TrkB,
TrkC, MET,
TIE2, VEGFR
1 48 June 2014
ALK, anaplastic lymphoma receptor tyrosine kinase; AXL, AXL receptor tyrosine kinase; c-kit, mast/stem cell growth factor receptor; CNS,
central nervous system; DDR2, discoidin domain receptor 2; Eph, ephrin receptor tyrosine kinases; FMS, McDonough Feline Sarcoma Viral;
MER, MER receptor tyrosine kinase; MET, hepatocyte growth factor receptor; PDGFR, platelet-derived growth factor receptor; RET,
rearranged during transfection; ROS1, ROS proto-oncogene 1; TIE2, TEK receptor tyrosine kinase; TRK, tropomyosin-related kinases (also
known as TrkA,B,C for kinase A, B and C); VEGFR, vascular endothelial growth factor receptor.
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anaplastic lymphoma kinase (ALK). Entrectinib can
cross the blood–brain barrier, and could thus potentially
be effective in the treatment of brain metastases and
GBM by activating gene fusions of NTRK, ROS1 or ALK.
Currently, two phase I trials are ongoing with this
drug;42–44 the RP2D of this drug is known and initial
reports of substantial antitumour activity in cancers har-
bouring NTRK1 gene fusions have been published.19 45
During screening for accrual in the European phase I
trial of entrectinib (EudraCT Number: 2014-001326-15),
the investigators identiﬁed a novel LMNA–NTRK1 gene
fusion in a patient with metastatic CRC who was enrolled
in the trial. The patient achieved a meaningful response
after only 1 month of treatment, suggesting for the ﬁrst
time that the NTRK gene may play a role as actionable
oncogenic driver in this tumour type as well.19 In
February 2015, entrectinib was granted FDA Orphan
Drug Designation for the treatment of TrkA, TrkB and
TrkC positive non-small cell lung and colorectal
tumours.41
LOXO-101 is a pan-Trk inhibitor with highly select-
ive activity against the Trk kinase family. To date, in
the phase I study, the maximum tolerated dose
(MTD) has not yet been reached and pharmacokinet-
ics show good systemic exposure of LOXO-101 after
oral dosing, reaching approximately 98% inhibition of
TrkA/B/C at peak concentrations with once daily
dosing of 50 or 100 mg.46 The clinical activity of this
inhibitor was recently reported47 in a case of a
41-year-old woman enrolled in the phase I trial who
showed remarkable tumour response after treatment
with LOXO-101.47 The report by Doebele et al47 also
identiﬁed a LMNA–NTRK1 gene fusion, previously
unreported in sarcoma.
Altiratinib (DCC-2701)48 and sitravatinib (MGCD516)49
are multikinase inhibitors with reported in vitro
activity against TrkA and TrkB, and were both
recently tested in phase I clinical trials. Other multiki-
nase inhibitors with claimed anti-Trk activity include
TSR-011, PLX7486, DS-6051b, F17752 and cabozantinib
(XL184), all in development in phase I/II trials
(table 2).
ACQUIRED RESISTANCE TO TRK INHIBITORS
As with other targeted therapies, the onset of acquired
(secondary) resistance may limit the efﬁcacy of Trk inhi-
bitors. Given their recent introduction into the thera-
peutic armamentarium of cancer treatment, very
limited data are available regarding mechanisms under-
lying resistance. Recently, a study by Russo et al unveiled
gene alterations associated with entrectinib-acquired
resistance. In particular, it has been reported that
entrectinib induced a remarkable clinical response in
mCRC carrying a LMNA-NTRK1 translocation, and
tumour resistance developed after 4 months of response
to discontinuous treatment (the cycle on which the
patient was treated consisted of 4 days on, 3 days off, for
3 weeks, followed by a 1 week break in dosing), when
the patient experienced progression of disease.19 To
characterise the molecular basis of acquired resistance
to entrectinib, circulating tumour DNA (ctDNA) was
collected longitudinally (liquid biopsies) during treat-
ment in this individual case, and a tumour biopsy was
obtained before entrectinib treatment and transplanted
into immunodeﬁcient mice in order to obtain a patient-
derived xenograft (PDX), which was challenged with
the same entrectinib regimen until resistance.50 The
study of ctDNA extracted from plasma samples collected
before treatment initiation and at clinical relapse
revealed two novel NTRK1 genetic alterations, p.G595R
and p.G667C, in the kinase domain of the protein,
which were not detected in the ctDNA pretreatment
but emerged in the circulation as early as 4 weeks from
beginning of treatment. This ﬁnding was strengthened
by the observation of the emergence of one of the
same molecular alterations, the NTRK1 p.G695R, in the
engrafted tumour biopsy expanded to multiple cohorts
of mice treated with dosage and schedule of entrectinib
matching those of the patient. The establishment of
independent preclinical models with acquired resistance
to entrectinib ﬁnally reinforced the conclusion that p.
G595R or p.G667C NTRK1 mutations are mechanisms
of resistance to entrectinib. The authors also concluded
that there is probably a dose-dependent effect affecting
the emergence of each of the two mutations: NTRK1 p.
G667C emerged with exposure of low concentration of
the inhibitor (absent with higher dose), and it is
weaker than p.G595R in conferring resistance.50 In the
reported case,19 indeed, the Trk pan-inhibitor entrecti-
nib was administered with an intermittent dosing
regimen that may have promoted or anticipated the
development of resistance. Nevertheless, it is still
unknown whether continuous or intermittent dosing
will affect the emergence and/or the type of acquired
mutations.
CONCLUSIONS AND FUTURE PERSPECTIVES
Gene fusions have been recognised as drivers in
tumours for more than three decades, providing useful
insights into carcinogenic processes. New deep-
sequencing technologies are now illuminating a land-
scape of previously undetected gene fusions in a multi-
tude of cancers.51 In such an expanding scenario, NTRK
gene fusions are emerging as novel targets across mul-
tiple tumour types, due to the growing availability of
new drugs with anti-Trk activity.
Clearly, a major challenge in the development of
these inhibitors is the low incidence in each single
tumour histology that is counterbalanced by a wide dis-
tribution of Trk alterations across multiple histologies,
thus increasing the number of patients who can be
reached and treated with matched therapeutics in
basket trials at the front edge of present clinical cancer
research.20 52
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